#RPTR-1-201
LightNews LightNews
newsen.bsky.social
Repertoire Immune Medicines Secures FDA Fast Track Designation for Innovative Cancer Treatment#United_States#Cambridge#RPTR-1-201#Repertoire_Immune_Medicines#fast_track_designation
Repertoire Immune Medicines Secures FDA Fast Track Designation for Innovative Cancer Treatment
Repertoire Immune Medicines has received FDA Fast Track Designation for RPTR-1-201, a promising treatment for triple-negative breast cancer, enhancing its development process.
third-news.com
May 7, 2026 at 12:37 PM
newsen.bsky.social
Repertoire Immune Medicines Doses First Patient in Groundbreaking Cancer Trial with Novel T Cell Therapy#United_States#Cambridge#T_Cell_Therapy#Repertoire_Immune#RPTR-1-201
Repertoire Immune Medicines Doses First Patient in Groundbreaking Cancer Trial with Novel T Cell Therapy
Repertoire Immune Medicines has announced the dosing of the first participant in a Phase 1/2 trial of RPTR-1-201, its innovative immune therapy aimed at treating advanced solid tumors.
third-news.com
April 23, 2026 at 12:36 PM
l2plabs.bsky.social
Repertoire Immune Medicines Appoints Robert Andtbacka, MD, CM, FACS, FRCSC, as Chief Medical Officer and Advances TCR Bispecific Development Candidate Toward the Clinic
Appointment of internationally recognized oncology expert and industry veteran strengthens the leadership team as Repertoire prepares to initiate first-in-human clinical trial of the TCR bispecific development candidate, RPTR-1-201 CAMBRIDGE, Mass., June 4, 2025 /PRNewswire/ --...
dlvr.it
June 4, 2025 at 12:04 PM